Welcure Drugs Agrees to 25% Stake Sale to Telexcell

Welcure Drugs will sell 25% of its shares to Telexcell, a Singapore-based company.

The deal, valued at ₹20 per share, is expected to be finalized in about three months.

Welcure's board approved the deal, rejecting Telexcell's request to influence management.

The main goal is to expand Welcure's business globally.

While Telexcell can provide suggestions, it won't have control over the company's decisions.

Welcure is not currently planning to raise additional funds.

This move should benefit both Welcure, its shareholders, and stakeholders.